Zealand Pharma revenue and financials
kr 247.40Change from previous close: −1.47%Absolute change: −kr 3.70
In the fiscal year ended December 2025, Zealand Pharma reported revenue of kr 9.21B (+14,598.86% year over year). Net income was kr 6.46B, a net margin of 70.0%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14,598.86%
- 2025 vs 2024
- Net margin
- 70.0%
- 2024: -1,720.9%
Financial data
Amounts in millions of DKK; per-share values in DKK; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 4,491 | 34.0 | 68.9 | 49.6 | 9,088 | — |
| Cost of revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Gross profit | 4,491 | 34.0 | 68.9 | 49.6 | 9,088 | — |
| Selling, general and administrative | 116 | 104 | -131 | 191 | 111 | — |
| Research and development | 516 | 469 | 530 | 320 | 464 | — |
| Operating income | 3,859 | -539 | -357 | -461 | 8,513 | — |
| EBIT | 4,014 | -389 | -399 | -360 | 8,118 | — |
| EBITDA | 4,025 | -379 | -391 | -352 | 8,125 | — |
| Interest expense | 8.0 | 5.0 | 7.1 | 7.0 | 7.0 | — |
| Pre-tax income | 4,006 | -394 | -407 | -367 | 8,111 | — |
| Income tax | 89.0 | 0.0 | -27.4 | 37.5 | 537 | — |
| Net income | 3,917 | -394 | -379 | -404 | 7,574 | — |
| Net income to common shareholders | 3,917 | -394 | -379 | -404 | 7,574 | — |
| Basic EPS | 55.68 | -5.58 | — | -5.75 | 107.09 | -4.74 |
| Diluted EPS | 55.34 | -5.58 | — | -5.75 | 105.61 | -4.74 |
| Average shares (basic) | 70.3 | 70.6 | — | 70.3 | 70.7 | 70.7 |
| Average shares (diluted) | 70.8 | 70.6 | — | 70.3 | 71.7 | 70.7 |